Steven Yu is an Oncology physician affiliated with University of California, San Francisco. OpenAlex indexes 24 publications with 1,017 citations (h-index 10).
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Industry payments
96 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year202518 payments
- AstraZeneca Pharmaceuticals LPProgram year202518 payments
- Novartis Pharmaceuticals CorporationProgram year202514 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
46.9%Serotonin-3 Receptor Antagonist46.3%Ondansetron hydrochloride96%Ondansetron Hcl3%Ondansetron Odt1%Part D + Part B<11 patientsProton pump inhibitor0.6%Omeprazole100%Part D<11 patientsSensory organs
37.5%Corticosteroid37.5%Dexamethasone sodium phosphate98%Dexamethasone Sodium Phosphate1%Dexamethasone1%Part D + Part B<11 patientsCancer & immunology
8.6%Kinase inhibitor2%Tagrisso37%Imatinib Mesylate26%Cabometyx20%Calquence17%Part D<11 patientsAromatase Inhibitor1.4%Anastrozole69%Letrozole31%Part D<11 patients+ 7 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- A Phase II Trial of AEZS-108 in Castration- and Taxane-Resistant Prostate Cancer
Clinical Genitourinary Cancer
2017 - Immunotherapy in urothelial cancer, part 1: T-cell checkpoint inhibition in advanced or metastatic disease.
PubMed
2017 - Immunotherapy in urothelial cancer, part 2: adjuvant, neoadjuvant, and adjunctive treatment.
PubMed
2017 - A phase II trial of zoptarelin doxorubicin in castration- and taxane-resistant prostate cancer.
Journal of Clinical Oncology
2017
Similar KOLs
Other experts from the same institution or the same specialty.
Talmadge King, MD
University of California, San Francisco
Adil Daud, MD
University of California, San Francisco
Emmanuelle Waubant, MD
University of California, San Francisco
Peter Ganz, MD
University of California, San Francisco
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Beth Karlan, MD
University of California, Los Angeles
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”